<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="343244">
  <stage>Registered</stage>
  <submitdate>27/07/2011</submitdate>
  <approvaldate>5/10/2011</approvaldate>
  <actrnumber>ACTRN12611001045909</actrnumber>
  <trial_identification>
    <studytitle>Identifying barriers to smoking cessation in rheumatoid arthritis</studytitle>
    <scientifictitle>The identification of barriers to smoking cessation in rheumatoid arthritis by focus groups</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Smoking</healthcondition>
    <healthcondition>Rheumatoid arthritis</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Rheumatoid arthritis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Addiction</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Focus groups will be undertaken to identify barriers to smoking cessation in patients with rheumatoid arthritis. Focus groups will be structured discussion groups lasting 2-3 hours. A varity of questionnaire will also be completed by each particpant including Health Assessmetn Questionnaire (HAQ), Arthritis Self-efficacy Scale, Percieved Stress Scale, Self efficacy scale, smoking history and the HADs depression and anxiety score. Participants will take part in one focus group and complete the questionnaires at the same time</interventions>
    <comparator>N/A</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Difference in questionaire results between groups of patients will be assessed using standard statistical methods</outcome>
      <timepoint>Single time of focus group</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Differences bought out in discussion in focus groups between groups of patients will be assessed using standard statistical methods</outcome>
      <timepoint>TIme of focus group</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>I. Male or female, aged  &gt;18yrs, with a diagnosis of RA as defined by the 2010 ACR/EULAR Criteria for RA 
II. Able and willing to give written informed consent and to adhere to the requirements of the study.
III. Current or past smoker.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Unable to give informed consent</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Psychosocial</purposeobs>
    <duration>Cross-sectional</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/01/2012</anticipatedstartdate>
    <actualstartdate>14/03/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate>15/04/2013</actualenddate>
    <samplesize>80</samplesize>
    <actualsamplesize>36</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Canterbury</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Otago</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Lisa Stamp</primarysponsorname>
    <primarysponsoraddress>Department of Medicine
University of Otago, Christchurch
P.O.Box 4345
Christchurch 8140</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Health Research Council of NZ</fundingname>
      <fundingaddress>PO Box 5541, Wellesley Street, Auckland 1141</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>University of Otago</sponsorname>
      <sponsoraddress>POBox 56 
Dunedin 9054</sponsoraddress>
      <sponsorcountry>New Zealand</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Charities/Societies/Foundations</othercollaboratortype>
      <othercollaboratorname>Arthritis New Zealand</othercollaboratorname>
      <othercollaboratoraddress>PO Box 10-020,The Terrace, Wellington, 6143</othercollaboratoraddress>
      <othercollaboratorcountry>New Zealand</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Rheumatoid arthritis is a common chronic disease resulting in joint damage requiring joint replacement surgery, disability and increased mortality due to cardiovascular disease. Smoking has recently been shown to be a powerful environmental risk factor for onset of RA. Smoking also results in worse disease outcomes and reduces the efficacy of medications used to treat RA. These effects, together with the increase in cardiovascular deaths make smoking cessation the most important modifiable lifestyle factor in RA. Such lifestyle changes are particularly difficult for patients living with the stress of a painful chronic disease. This project will explore the knowledge and beliefs of patients with RA in relation to smoking as it affects their condition. Specific arthritis related factors that contribute to difficulties with smoking cessation will be explored. A RA-specific smoking cessation programme will then be developed based on the findings and piloted in patients with RA with the help of Arthritis New Zealand.</summary>
    <trialwebsite>Nil</trialwebsite>
    <publication>Aimer P, Stamp LK, Stebbings S, Valentino V, Cameron V and Treharne GT. Identifying Barriers to Smoking Cessation in Rheumatoid Arthritis. Arthritis Care Res 2015; 67(5); 607-15.</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Multiregional Ethics Committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate>19/07/2011</ethicapprovaldate>
      <hrec>MEC/11/06/061</hrec>
      <ethicsubmitdate>1/07/2011</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Lisa Stamp</name>
      <address>Department of Medicine
University of Otago, Christchurch
P.O.Box 4345
Christchurch 8014</address>
      <phone>+64-3-364-0953</phone>
      <fax>+64-3-364-0935</fax>
      <email>lisa.stamp@cdhb.health.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Lisa Stamp</name>
      <address>Department of Medicine
University of Otago, Christchurch
P.O.Box 4345
Christchurch 8014</address>
      <phone>+64-3-364-0953</phone>
      <fax>+64-3-364-0935</fax>
      <email>lisa.stamp@cdhb.health.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Lisa Stamp</name>
      <address>Department of Medicine
University of Otago, Christchurch
P.O.Box 4345
Christchurch 8014</address>
      <phone>+64-3-364-0953</phone>
      <fax>+64-3-364-0935</fax>
      <email>lisa.stamp@cdhb.health.nz</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Lisa Stamp</name>
      <address>Department of Medicine
P.O.Box 4345
Christchurch 8014</address>
      <phone>+643640953</phone>
      <fax />
      <email>lisa.stamp@cdhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>